Detalle Publicación

ARTÍCULO
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Autores: Krop, Ian E.; Kim, Sung-Bae; González Martín, Antonio; LoRusso, Patricia M.; Ferrero, Jean-Marc; Smitt, Melanie; Yu, Ron; Leung, Abraham C. F.; Wildiers, Hans; TH3RESA Study Collaborators
Título de la revista: LANCET ONCOLOGY
ISSN: 1474-5488
Volumen: 15
Número: 7
Páginas: 689-699
Fecha de publicación: 2014
Resumen:
Trastuzumab emtansine should be considered as a new standard for patients with HER2-positive advanced breast cancer who have previously received trastuzumab and lapatinib.